Applied Therapeutics (APLT) Price & Analysis

Compare

885 Followers

APLT Stock Chart & Stats

$0.12

-$0.07(-8.39%)

At close: Jan 08 4:00 PM EST

$0.12

-$0.07(-8.39%)

Day’s Range― - ―

52-Week Range$0.11 - $1.50

Previous CloseN/A

Volume3.84M

Average Volume (3M)17.54M

Market Cap

$16.65M

Enterprise Value$78.60M

Total Cash (Recent Filing)$11.95M

Total Debt (Recent Filing)$2.50M

Price to Earnings (P/E)―

Beta2.05

Next Earnings

Mar 13, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding144,300,670

10 Day Avg. Volume47,414,159

30 Day Avg. Volume17,542,089

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)2.10

Price to Sales (P/S)262.57

P/FCF Ratio-1.42

Enterprise Value/Market Cap4.72

Enterprise Value/Revenue78.60

Enterprise Value/Gross Profit-2.76

Enterprise Value/Ebitda-0.78

Forecast

1Y Price Target

$0.25

Price Target Upside108.33% Upside

Rating ConsensusHold

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trials And Regulatory ApprovalA new clinical trial entry suggests that the company may have aligned on accelerated approval for their drug Govorestat in SORD.

Market SentimentThe stock is up about 80% during market hours, indicating positive market sentiment based on the clinical trial entry.

Strategic AcquisitionThe acquisition by Cycle Group Holdings Limited could provide a fresh start for govorestat.

Bears Say

Commercialization ChallengesApplied was not in a position to advance the asset to commercialization at this time.

Financial RiskThe company bears increased financial risk due to its limited cash runway of $30.4 million as of June 30.

Regulatory UncertaintyAn NDA for accelerated approval in the near term may be unlikely for govorestat.

Applied Therapeutics News

Applied Therapeutics downgraded to Neutral from Outperform at Baird

Baird analyst Brian Skorney downgraded Applied Therapeutics (APLT) to Neutral from Outperform with a price target of 25c,...

15d ago

APLT

Applied Therapeutics trading resumes

17:55 EST Applied Therapeutics (APLT) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

15d ago

APLT

Applied Therapeutics to be acquired by Cycle Pharmaceuticals

Applied Therapeutics (APLT) announced a definitive agreement for Cycle Group to acquire Applied Therapeutics. Cycle will commence a...

15d ago

APLT

Applied Therapeutics trading halted, news pending

17:21 EST Applied Therapeutics (APLT) trading halted, news pending Published first on TheFly – the ultimate source for...

15d ago

APLT

Applied Therapeutics downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Applied Therapeutics (APLT) to Market Perform from Outperform with a price target of $1, down from...

24d ago

APLT

Applied Therapeutics Announces Merger with Cycle Group

Applied Therapeutics ( ($APLT) ) has shared an update. On December 11, 2025, Applied Therapeutics announced a merger...

15d ago

APLT

Hold Rating on Applied Therapeutics Amid Uncertainty of Acquisition and CVR Milestones

William Blair analyst Sami Corwin has maintained their neutral stance on APLT stock, giving a Hold rating on...

15d ago

APLT

Hold Rating Issued for Applied Therapeutics Amid Strategic Alternatives and Govorestat Uncertainty

William Blair analyst Sami Corwin has reiterated their neutral stance on APLT stock, giving a Hold rating on...

1M ago

APLT

Applied Therapeutics Announces Strategic Review and Workforce Cuts

An announcement from Applied Therapeutics ( ($APLT) ) is now available. On November 20, 2025, Applied Therapeutics announced...

1M ago

APLT

Applied Therapeutics explores strategic alternatives, reduces workforce by 46%

Applied Therapeutics (APLT) announced that Applied Therapeutics’ Board of Directors has initiated a process to explore strategic alternatives...

1M ago

APLT

Applied Therapeutics to request additional Type C meeting regarding govorestat

As previously announced, the Company completed a Type C meeting with the United States Food and Drug Administration...

1M ago

APLT

Applied Therapeutics Reports Quarterly Financial Results

Applied Therapeutics ( ($APLT) ) has released its Q3 earnings. Here is a breakdown of the information Applied...

1M ago

APLT

Applied Therapeutics reports Q3 EPS (13c), consensus (14c)

Reports Q3 revenue $1M, consensus $250k. “Our ongoing efforts in operational execution and regulatory progress have yielded important...

1M ago

APLT

Applied Therapeutics announces resignation of Executive Chairman Johnson

Board Leadership Transition: In November 2025, John Johnson informed the Board of Directors of his decision to step...

1M ago

APLT

APLT FAQ

What was Applied Therapeutics Inc’s price range in the past 12 months?

Applied Therapeutics Inc lowest stock price was $0.11 and its highest was $1.50 in the past 12 months.

What is Applied Therapeutics Inc’s market cap?

Applied Therapeutics Inc’s market cap is $16.65M.

When is Applied Therapeutics Inc’s upcoming earnings report date?

Applied Therapeutics Inc’s upcoming earnings report date is Mar 13, 2026 which is in 76 days.

How were Applied Therapeutics Inc’s earnings last quarter?

Applied Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.141 by $0.011.

Is Applied Therapeutics Inc overvalued?

According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Applied Therapeutics Inc pay dividends?

Applied Therapeutics Inc does not currently pay dividends.

What is Applied Therapeutics Inc’s EPS estimate?

Applied Therapeutics Inc’s EPS estimate is -0.12.

How many shares outstanding does Applied Therapeutics Inc have?

Applied Therapeutics Inc has 144,300,670 shares outstanding.

What happened to Applied Therapeutics Inc’s price movement after its last earnings report?

Applied Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.141. Following the earnings report the stock price went down -70.33%.

Which hedge fund is a major shareholder of Applied Therapeutics Inc?

Currently, no hedge funds are holding shares in APLT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Applied Therapeutics Inc

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics (APLT) Earnings & Revenues

Historic Earnings Reports

APLT Stock 12 Month Forecast

Average Price Target

$0.25

▲(108.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.24,0.24076923076923076,0.24153846153846154,0.2423076923076923,0.24307692307692308,0.24384615384615385,0.24461538461538462,0.24538461538461537,0.24615384615384614,0.2469230769230769,0.24769230769230768,0.24846153846153846,0.24923076923076923,{"y":0.25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.24,0.24076923076923076,0.24153846153846154,0.2423076923076923,0.24307692307692308,0.24384615384615385,0.24461538461538462,0.24538461538461537,0.24615384615384614,0.2469230769230769,0.24769230769230768,0.24846153846153846,0.24923076923076923,{"y":0.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.24,0.24076923076923076,0.24153846153846154,0.2423076923076923,0.24307692307692308,0.24384615384615385,0.24461538461538462,0.24538461538461537,0.24615384615384614,0.2469230769230769,0.24769230769230768,0.24846153846153846,0.24923076923076923,{"y":0.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.61,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.66,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.41,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.24,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >